uniQure (QURE) Competitors $14.47 -0.37 (-2.49%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$14.62 +0.15 (+1.00%) As of 09/16/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock QURE vs. MIRM, MLTX, MTSR, PTGX, AAPG, LNTH, AKRO, APLS, ZLAB, and CRNXShould you be buying uniQure stock or one of its competitors? The main competitors of uniQure include Mirum Pharmaceuticals (MIRM), MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), Lantheus (LNTH), Akero Therapeutics (AKRO), Apellis Pharmaceuticals (APLS), Zai Lab (ZLAB), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry. uniQure vs. Its Competitors Mirum Pharmaceuticals MoonLake Immunotherapeutics Metsera Protagonist Therapeutics Ascentage Pharma Group International Lantheus Akero Therapeutics Apellis Pharmaceuticals Zai Lab Crinetics Pharmaceuticals Mirum Pharmaceuticals (NASDAQ:MIRM) and uniQure (NASDAQ:QURE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment. Does the media prefer MIRM or QURE? In the previous week, Mirum Pharmaceuticals had 11 more articles in the media than uniQure. MarketBeat recorded 12 mentions for Mirum Pharmaceuticals and 1 mentions for uniQure. uniQure's average media sentiment score of 0.95 beat Mirum Pharmaceuticals' score of 0.37 indicating that uniQure is being referred to more favorably in the news media. Company Overall Sentiment Mirum Pharmaceuticals Neutral uniQure Positive Do analysts recommend MIRM or QURE? Mirum Pharmaceuticals currently has a consensus price target of $74.44, indicating a potential upside of 0.89%. uniQure has a consensus price target of $37.45, indicating a potential upside of 158.84%. Given uniQure's higher probable upside, analysts clearly believe uniQure is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11uniQure 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has more volatility & risk, MIRM or QURE? Mirum Pharmaceuticals has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, uniQure has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. Do insiders & institutionals believe in MIRM or QURE? 78.8% of uniQure shares are owned by institutional investors. 22.9% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 4.8% of uniQure shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is MIRM or QURE more profitable? Mirum Pharmaceuticals has a net margin of -13.65% compared to uniQure's net margin of -1,387.98%. Mirum Pharmaceuticals' return on equity of -24.76% beat uniQure's return on equity.Company Net Margins Return on Equity Return on Assets Mirum Pharmaceuticals-13.65% -24.76% -8.50% uniQure -1,387.98%-1,010.74%-33.27% Which has better earnings & valuation, MIRM or QURE? Mirum Pharmaceuticals has higher revenue and earnings than uniQure. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMirum Pharmaceuticals$336.89M11.00-$87.94M-$1.21-60.98uniQure$27.12M29.28-$239.56M-$3.92-3.69 SummaryMirum Pharmaceuticals beats uniQure on 11 of the 17 factors compared between the two stocks. Get uniQure News Delivered to You Automatically Sign up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QURE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QURE vs. The Competition Export to ExcelMetricuniQureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$813.95M$3.12B$5.73B$10.31BDividend YieldN/A2.36%5.90%4.63%P/E Ratio-3.6921.1675.8626.51Price / Sales29.28446.35528.72123.58Price / CashN/A45.4037.1760.46Price / Book-103.369.6212.796.29Net Income-$239.56M-$53.28M$3.28B$270.51M7 Day Performance-17.22%1.01%0.81%1.95%1 Month Performance-10.57%4.58%4.60%6.33%1 Year Performance157.47%8.35%70.39%25.62% uniQure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QUREuniQure3.2687 of 5 stars$14.47-2.5%$37.45+158.8%+167.5%$813.95M$27.12M-3.69500MIRMMirum Pharmaceuticals3.3294 of 5 stars$76.06+2.5%$74.13-2.5%+82.6%$3.82B$336.89M-62.86140Positive NewsMLTXMoonLake Immunotherapeutics2.4965 of 5 stars$59.44-0.5%$74.43+25.2%+6.6%$3.82BN/A-21.382High Trading VolumeMTSRMetseraN/A$35.87-1.2%$59.00+64.5%N/A$3.77BN/A0.0081Analyst UpgradeGap UpPTGXProtagonist Therapeutics2.321 of 5 stars$60.53+1.6%$67.20+11.0%+26.8%$3.77B$434.43M86.47120Positive NewsAnalyst RevisionHigh Trading VolumeAAPGAscentage Pharma Group InternationalN/A$40.50+5.0%N/AN/A$3.76B$134.35M0.00600News CoveragePositive NewsLNTHLantheus4.5409 of 5 stars$54.75+1.7%$91.60+67.3%-51.7%$3.72B$1.53B14.56700Trending NewsAnalyst ForecastAKROAkero Therapeutics3.883 of 5 stars$44.72+1.6%$81.14+81.4%+59.1%$3.58BN/A-22.3630Positive NewsAPLSApellis Pharmaceuticals4.2869 of 5 stars$28.13-1.8%$34.12+21.3%-34.4%$3.55B$781.37M-15.46770Positive NewsZLABZai Lab3.0547 of 5 stars$30.76+2.5%$56.35+83.2%+56.2%$3.44B$398.99M-15.081,869Gap UpCRNXCrinetics Pharmaceuticals3.7196 of 5 stars$35.61+4.0%$68.86+93.4%-36.8%$3.35B$1.04M-8.66210Positive News Related Companies and Tools Related Companies MIRM Alternatives MLTX Alternatives MTSR Alternatives PTGX Alternatives AAPG Alternatives LNTH Alternatives AKRO Alternatives APLS Alternatives ZLAB Alternatives CRNX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QURE) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding uniQure N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share uniQure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QURE Stock Alerts